间充质干细胞
细胞外小泡
间质细胞
微泡
再生医学
体内
细胞生物学
体外
生物
蛋白质组
干细胞
化学
计算生物学
生物信息学
癌症研究
小RNA
生物化学
生物技术
基因
作者
Bas W. M. van Balkom,Hendrik Gremmels,Bernd Giebel,Sai Kiang Lim
出处
期刊:Proteomics
[Wiley]
日期:2019-01-01
卷期号:19 (1-2)
被引量:81
标识
DOI:10.1002/pmic.201800163
摘要
Abstract Small extracellular vesicles (EVs) are 50–200 nm vesicles secreted by most cells. They are considered as mediators of intercellular communication, and EVs from specific cell types, in particular mesenchymal stem/stromal cells (MSCs), offer powerful therapeutic potential, and can provide a novel therapeutic strategy. They appear promising and safe (as EVs are non‐self‐replicating), and eventually MSC‐derived EVs (MSC‐EVs) may be developed to standardized, off‐the‐shelf allogeneic regenerative and immunomodulatory therapeutics. Promising pre‐clinical data have been achieved using MSCs from different sources as EV‐producing cells. Similarly, a variety EV isolation and characterization methods have been applied. Interestingly, MSC‐EVs obtained from different sources and prepared with different methods show in vitro and in vivo therapeutic effects, indicating that isolated EVs share a common potential. Here, well‐characterized and controlled, publicly available proteome profiles of MSC‐EVs are compared to identify a common MSC‐EV protein signature that might be coupled to the MSC‐EVs’ common therapeutic potential. This protein signature may be helpful in developing MSC‐EV quality control platforms required to confirm the identity and test for the purity of potential therapeutic MSC‐EVs.
科研通智能强力驱动
Strongly Powered by AbleSci AI